Gleason Score is used to grade which cancer –
## **Core Concept**
The Gleason Score is a system used for grading prostate cancer based on the microscopic appearance of tumor tissue. It assesses the aggressiveness of prostate cancer by evaluating the glandular differentiation of the tumor. The score is crucial for determining the prognosis and guiding treatment decisions.
## **Why the Correct Answer is Right**
The Gleason Score is specifically designed for prostate cancer. It involves examining the tumor tissue under a microscope and grading it based on how much the tumor cells resemble normal prostate cells. The score ranges from 2 to 10, with higher scores indicating a worse prognosis. This scoring system helps in predicting the likelihood of cancer spread and patient survival.
## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because the Gleason Score is not used for grading lung cancer. Lung cancer grading is based on different criteria, such as the tumor size, lymph node involvement, and presence of metastasis (TNM staging).
- **Option B:** This option is incorrect because the Gleason Score is not applicable to breast cancer. Breast cancer grading is typically done using the Nottingham Histologic Score or the Scarff-Bloom-Richardson grading system.
- **Option C:** This option is incorrect because, although liver cancer (hepatocellular carcinoma) has various grading systems, the Gleason Score is not used for this purpose.
- **Option D:** While this option might seem plausible due to the context of the question, the correct association is with prostate cancer, making the other options clearly incorrect.
## **Clinical Pearl / High-Yield Fact**
A key point to remember is that the Gleason Score is a critical tool in the management of prostate cancer. A higher Gleason Score indicates a more aggressive form of cancer. For example, a Gleason Score of 6 or less often indicates a less aggressive cancer, whereas a score of 8-10 suggests a more aggressive tumor.
## **Correct Answer:** B. Prostate cancer.